Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Increased Activated Circulating T Follicular Helper Cells and Changes in B Cell Subsets in Immune TTP (iTTP) and in Response to Rituximab Treatment

Jin-Sup Shin, Geraldine Cambridge, PhD, Yanping Guo, DPhil, Marie Scully, MD, Mari Thomas

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-140337

Published: 2020

Journal Articles

Long-Term Safety and Efficacy of Sutimlimab in Patients with Chronic Immune Thrombocytopenia

Catherine M. Broome, Alexander Röth, MD, David J. Kuter, MD, Marie Scully, MD, Roy Smith, Jennifer Wang, Xiaoyu Jiang, Caroline Reuter, Ahmed Daak, William Hobbs

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-139663

Published: 2020

Journal Articles

Plasma Exchange for COVID-19 Thrombo-Inflammatory Disease

Mari Thomas, Nishkantha Arulkumaran, David Brearley, Ferras Alwan, Deepak Singh, Michael P Lunn, Anna Welch, Samuel Clark, Eamon Raith, Ugan Reddy, Ryan Low, David Leverett, Mervyn Singer, Marie Scully, MD

Blood (2020) 136 (Supplement 1): 27.

https://doi.org/10.1182/blood-2020-138851

Published: 2020

Journal Articles

Factors Influencing Time from Initial Presentation to Start of Plasma Exchange (PEX) in Patients with Acute Thrombotic Thrombocytopenic Purpura (TTP)

Rory McCulloch, FRCPath, MRCP, MBBS, Tom Bull, MBBS,FRCPath,MRCP, Phillip LR Nicolson, MA, MBBChir, MRCP, Rebecca J Shaw, MRCP, Zara Sayar, MD FRCPath, MRCP, Alexander Langridge, Michala Pettitt, PhD, Rita Perry, David Tucker, MD, Marie Scully, MD, HaemSTAR Collaborators. (# joint first authors)

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-133371

Published: 2020

Journal Articles

Safety of Caplacizumab for the Treatment of Patients with Acquired Thrombotic Thrombocytopenic Purpura - Results Normalized to Time of Exposure in a Double-Blind, Placebo-Controlled, Phase 3 Hercules Study

Johanna A. Kremer Hovinga, MD Prof, Marie Scully, MD MRCP, FRCPath, Spero R Cataland, MD, Flora Peyvandi, MD PhD, Paul Coppo, MD PhD, Paul Knöbl, MD PhD, Javier De La Rubia, MD, Katerina Pavenski, MD, Jessica Minkue, Rui Passos Sousa, MD MSc, Filip Callewaert, PhD, Hilde De Winter, MD, Ara Metjian, MD

Blood (2018) 132 (Supplement 1): 3744.

https://doi.org/10.1182/blood-2018-99-112177

Published: 2018

Journal Articles

Single Centre UK Comparison of Biosimilar Rituximab (Truxima) with the Originator (MabThera) in Patients with Immune Mediated Thrombotic Thrombocytopenic Purpura

Matthew J. Stubbs, MBBS, MRCP, FRCPath, Ryan Low, MBChB, Siobhan McGuckin, Rosalind Newton, John-Paul Westwood, MD, Mari Thomas, PhD, Simon Cheesman, BPharm, Marie Scully, MD MRCP, FRCPath

Blood (2018) 132 (Supplement 1): 3750.

https://doi.org/10.1182/blood-2018-99-114765

Published: 2018

Journal Articles

Integrated Efficacy Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura

Flora Peyvandi, MD PhD, Spero R Cataland, MD, Marie Scully, MD MRCP, FRCPath, Paul Coppo, MD PhD, Paul Knöbl, MD PhD, Johanna A. Kremer Hovinga, MD Prof, Ara Metjian, MD, Javier De La Rubia, MD, Katerina Pavenski, MD, Jessica Minkue, Filip Callewaert, PhD, Hilde De Winter, MD

Blood (2018) 132 (Supplement 1): 373.

https://doi.org/10.1182/blood-2018-99-112125

Published: 2018

Journal Articles

Integrated Safety Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura

Paul Knöbl, MD PhD, Marie Scully, MD MRCP, FRCPath, Spero R Cataland, MD, Flora Peyvandi, MD PhD, Paul Coppo, MD PhD, Johanna A. Kremer Hovinga, MD Prof, Ara Metjian, MD, Javier De La Rubia, MD, Katerina Pavenski, MD, Jessica Minkue, Filip Callewaert, PhD, Hilde De Winter, MD

Blood (2018) 132 (Supplement 1): 3739.

https://doi.org/10.1182/blood-2018-99-112174

Published: 2018

Journal Articles

A New Flow-Based Assay to Assess Treatment Response in Congenital Thrombotic Thrombocytopenic Purpura

Ferras Alwan, Chiara Vendramin, Alice Taylor, Mari Thomas, PhD, Ri Liesner, Marie Scully, MD MRCP, FRCPath

Blood (2018) 132 (Supplement 1): 2441.

https://doi.org/10.1182/blood-2018-99-115965

Published: 2018

Journal Articles

Real World Use of Thrombopoietin-Receptor Agonists in the Management of Immune Thrombocytopenia in the United Kingdom: Results from the TRAIT Study

Nichola Cooper, MRCP, Andrew Provan, Marie Scully, MD MRCP, FRCPath, Henri Grech, Catherine Bagot, MD FRCPath, MBBS, Quentin A Hill, BSc, MBChB, MRCP, FRCPath, Tim Nokes, Nicholas Ramscar, Luke Saunders

Blood (2018) 132 (Supplement 1): 2426.

https://doi.org/10.1182/blood-2018-99-110126

Published: 2018

Journal Articles

Risk Factors and Manageability of the Mainly Mild Mucocutaneous Bleeding Profile Observed in Attp Patients Treated with Caplacizumab during the Phase III Hercules Study

Spero R Cataland, MD, Marie Scully, MD MRCP, FRCPath, Flora Peyvandi, MD PhD, Paul Coppo, MD PhD, Paul Knöbl, MD PhD, Johanna A. Kremer Hovinga, MD Prof, Ara Metjian, MD, Javier De La Rubia, MD, Katerina Pavenski, MD, Jessica Minkue, Rui Passos Sousa, MD MSc, Filip Callewaert, PhD, Hilde De Winter, MD

Blood (2018) 132 (Supplement 1): 1142.

https://doi.org/10.1182/blood-2018-99-112179

Published: 2018

Journal Articles

Use of Eculizumab for the Treatment of Hyperhaemolysis in Pregnancy in Sickle Cell Disease: A Case Report

Laura Chebet Kirui, MRCP, FRCPath, Marie Scully, MD MRCP, FRCPath, Norma Mcqueen, Bsc, John Porter, MA MDFRCP FRCPath, Perla Eleftheriou, FRCPath, MRCP

Blood (2018) 132 (Supplement 1): 4922.

https://doi.org/10.1182/blood-2018-99-118396

Published: 2018

Journal Articles

Results of the Randomized, Double-Blind, Placebo-Controlled, Phase 3 Hercules Study of Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura

Marie Scully, MD, Spero R Cataland, MD, Flora Peyvandi, MD PhD, Paul Coppo, MD PhD, Paul Knöbl, MD PhD, Johanna A. Kremer Hovinga, MD, Ara Metjian, MD, Javier de la Rubia, MD, Katerina Pavenski, MD, Filip Callewaert, PhD, Debjit Biswas, PhD, Hilde De Winter, MD, Robert K. Zeldin, MD

Blood (2017) 130 (Supplement 1): LBA-1.

https://doi.org/10.1182/blood.V130.Suppl_1.LBA-1.LBA-1

Published: 2017

Journal Articles

A Phase II Study to Assess the Safety, Efficacy and Tolerability of Rituximab (Mabthera) In Combination with Plasma Exchange In Patients with Acute Thrombotic Thrombocytopenic Purpura (TTP).

Marie Scully, MD, James D Cavenagh, MD, Beverley Hunt, MD, Vicki McDonald, MD, Samuel J Machin, MD

Blood (2010) 116 (21): 3699.

https://doi.org/10.1182/blood.V116.21.3699.3699

Published: 2010

Journal Articles

A Phase II Study To Assess the Safety, Efficacy and Tolerability of Rituximab in Combination with Plasma Exchange in Patients with Acute Idiopathic Thrombotic Thrombocytopenic Purpura.

Marie Scully, MD, Jamie Cavenagh, MD, Beverley Hunt, MD, Hannah Cohen, MD, Samuel J. Machin, MD

Blood (2007) 110 (11): 1303.

https://doi.org/10.1182/blood.V110.11.1303.1303

Published: 2007

Journal Articles

Acute Idiopathic Thrombotic Thrombocytopenic Purpura: Predicting Relapse and Response to Treatment.

Marie Scully, MD, Richard Starke, PhD, Ian Mackie, PhD, Samuel J. Machin, MD

Blood (2006) 108 (11): 1059.

https://doi.org/10.1182/blood.V108.11.1059.1059

Published: 2006

Journal Articles

The South East England Thrombotic Thrombocytopenic Purpura Registry.

Marie Scully, MD, Helen Yarranton, MD, Ri Liesner, MD, Jamie Cavenagh, MD, Beverley Hunt, MD, Sylvia Benjamin, MD, Michael Laffan, MD, David Bevan, MD, Ian Mackie, PhD, Samuel J. Machin, MD

Blood (2006) 108 (11): 1064.

https://doi.org/10.1182/blood.V108.11.1064.1064

Published: 2006

Journal Articles

Cryosupernatant and Solvent Detergent Fresh Frozen Plasma (Octaplas, Octapharma) Usage in Acute Thrombotic Thrombocytopenic Purpura-Review of 50 Episodes.

Marie Scully, MD, Michael Flynn, Jenny Berryman, Samuel J. Machin, MD

Blood (2006) 108 (11): 4139.

https://doi.org/10.1182/blood.V108.11.4139.4139

Published: 2006

NARROW

Increased Activated Circulating T Follicular Helper Cells and Changes in B Cell Subsets in Immune TTP (iTTP) and in Response to Rituximab Treatment

Long-Term Safety and Efficacy of Sutimlimab in Patients with Chronic Immune Thrombocytopenia

Plasma Exchange for COVID-19 Thrombo-Inflammatory Disease

Factors Influencing Time from Initial Presentation to Start of Plasma Exchange (PEX) in Patients with Acute Thrombotic Thrombocytopenic Purpura (TTP)

Safety of Caplacizumab for the Treatment of Patients with Acquired Thrombotic Thrombocytopenic Purpura - Results Normalized to Time of Exposure in a Double-Blind, Placebo-Controlled, Phase 3 Hercules Study

Single Centre UK Comparison of Biosimilar Rituximab (Truxima) with the Originator (MabThera) in Patients with Immune Mediated Thrombotic Thrombocytopenic Purpura

Integrated Efficacy Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura

Integrated Safety Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura

A New Flow-Based Assay to Assess Treatment Response in Congenital Thrombotic Thrombocytopenic Purpura

Real World Use of Thrombopoietin-Receptor Agonists in the Management of Immune Thrombocytopenia in the United Kingdom: Results from the TRAIT Study

Risk Factors and Manageability of the Mainly Mild Mucocutaneous Bleeding Profile Observed in Attp Patients Treated with Caplacizumab during the Phase III Hercules Study

Use of Eculizumab for the Treatment of Hyperhaemolysis in Pregnancy in Sickle Cell Disease: A Case Report

Results of the Randomized, Double-Blind, Placebo-Controlled, Phase 3 Hercules Study of Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura

A Phase II Study to Assess the Safety, Efficacy and Tolerability of Rituximab (Mabthera) In Combination with Plasma Exchange In Patients with Acute Thrombotic Thrombocytopenic Purpura (TTP).

A Phase II Study To Assess the Safety, Efficacy and Tolerability of Rituximab in Combination with Plasma Exchange in Patients with Acute Idiopathic Thrombotic Thrombocytopenic Purpura.

Acute Idiopathic Thrombotic Thrombocytopenic Purpura: Predicting Relapse and Response to Treatment.

The South East England Thrombotic Thrombocytopenic Purpura Registry.

Cryosupernatant and Solvent Detergent Fresh Frozen Plasma (Octaplas, Octapharma) Usage in Acute Thrombotic Thrombocytopenic Purpura-Review of 50 Episodes.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only